Epiomic Epidemiology Series: Primary Immunodeficiency Disease Forecast in 21 Major Markets 2016-2026

Black Swan Analysis
76 Pages - BSA10047
$6,400.00

Primary immunodeficiency diseases (PID) are a group of inherited genetic disorders of the genes governing the immune system. PIDs are a group of more than 200 rare, chronic disorders in which part of the body’s immune system is missing or functions improperly. Some types of PID affect a single part of the immune system while others may affect one or more components of the system.

This report provides the current prevalent population for PID disease across 21 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan, India, Switzerland, Netherlands, Turkey, Sweden, Belgium, Poland, Hungary, Czech Republic, Austria, Greece, Argentina and Mexico) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team, several of the main syndromes and sub-classifications of PID have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for PID include:

• Severe Congenital Immunodeficiency (SCID)
• Recurrent or persistent infections
• Allergic manifestations
• Respiratory diseases
• Organ Problems
• Developmental delay

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Please be aware that for some markets represented within this report, data is unavailable due to some markets being unable to report the same classifications and sub-classifications that are reported in other markets.

Reason to buy

• Able to quantify patient populations in global PID’s market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of PID and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on PID’s prevalent population.
• Identify sub-populations within PID which require treatment.
• Gain an understanding of the specific markets that have the largest number of PID patients.


'

Table of Contents
• List of Tables and Figures
• Introduction
• Cause of the Disease
• Risk Factors & Prevention
• Diagnosis of the Disease
• Variation by Geography/Ethnicity
• Disease Prognosis & Clinical Course
• Key Co-morbid Conditions/ Features Associated with the Disease
• Methodology for Quantification of Patient Numbers
• Top-Line Prevalence for PID
o Classification of PID Patients
o Subclassification of Primary Immunodeficient Patients with Ab Deficiency
o Subclassification of PID Patients with CD
o Other Well-Defined Syndromes with PID
o SCID Co-morbid Condition within PID
• Abbreviations used in the Report
• Other Black Swan Analysis Publications
• Black Swan Analysis Online Patient-Based Databases
• Patient-Based Offering
• Online Pricing Data and Platforms
• References
• Appendix


List of Tables
• Prevalence of PID, total (000s)
• Prevalence of PID, males (000s)
• Prevalence of PID, females (000s)
• Classification of PID patients, total (000s)
• Types of Ab Deficiency in PID patients, total (000s)
• Types of Complement Deficiencies of PID patients, total (000s)
• Types of Other Well-Defined Syndromes with PID patients, total (000s)
• Types of SCID within PID, total (000s)
• Abbreviations and Acronyms used in the report
• USA Prevalence of PID by 5-yr age cohort, males (000s)
• USA Prevalence of PID by 5-yr age cohort, females (000s)
• France Prevalence of PID by 5-yr age cohort, males (000s)
• France Prevalence of PID by 5-yr age cohort, females (000s)
• Germany Prevalence of PID by 5-yr age cohort, males (000s)
• Germany Prevalence of PID by 5-yr age cohort, females (000s)
• Italy Prevalence of PID by 5-yr age cohort, males (000s)
• Italy Prevalence of PID by 5-yr age cohort, females (000s)
• Spain Prevalence of PID by 5-yr age cohort, males (000s)
• Spain Prevalence of PID by 5-yr age cohort, females (000s)
• United Kingdom Prevalence of PID by 5-yr age cohort, males (000s)
• United Kingdom Prevalence of PID by 5-yr age cohort, females (000s)
• Brazil Prevalence of PID by 5-yr age cohort, males (000s)
• Brazil Prevalence of PID by 5-yr age cohort, females (000s)
• Japan Prevalence of PID by 5-yr age cohort, males (000s)
• Japan Prevalence of PID by 5-yr age cohort, females (000s)
• India Prevalence of PID by 5-yr age cohort, males (000s)
• India Prevalence of PID by 5-yr age cohort, females (000s)
• Switzerland Prevalence of PID by 5-yr age cohort, males (000s)
• Switzerland Prevalence of PID by 5-yr age cohort, females (000s)
• Netherlands Prevalence of PID by 5-yr age cohort, males (000s)
• Netherlands Prevalence of PID by 5-yr age cohort, females (000s)
• Turkey Prevalence of PID by 5-yr age cohort, males (000s)
• Turkey Prevalence of PID by 5-yr age cohort, females (000s)
• Sweden Prevalence of PID by 5-yr age cohort, males (000s)
• Sweden Prevalence of PID by 5-yr age cohort, females (000s)
• Belgium Prevalence of PID by 5-yr age cohort, males (000s)
• Belgium Prevalence of PID by 5-yr age cohort, females (000s)
• Poland Prevalence of PID by 5-yr age cohort, males (000s)
• Poland Prevalence of PID by 5-yr age cohort, females (000s)
• Hungary Prevalence of PID by 5-yr age cohort, males (000s)
• Hungary Prevalence of PID by 5-yr age cohort, females (000s)
• CZR Prevalence of PID by 5-yr age cohort, males (000s)
• CZR Prevalence of PID by 5-yr age cohort, females (000s)
• Austria Prevalence of PID by 5-yr age cohort, males (000s)
• Austria Prevalence of PID by 5-yr age cohort, females (000s)
• Greece Prevalence of PID by 5-yr age cohort, males (000s)
• Greece Prevalence of PID by 5-yr age cohort, females (000s)
• Argentina Prevalence of PID by 5-yr age cohort, males (000s)
• Argentina Prevalence of PID by 5-yr age cohort, females (000s)
• Argentina Prevalence of PID by 5-yr age cohort, females (000s)
• Mexico Prevalence of PID by 5-yr age cohort, females (000s)
• Mexico Prevalence of PID by 5-yr age cohort, females (000s)

$6,400.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838